Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05257083 · ClinicalTrials.gov registry record · Phase 3

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

A Phase 3 study of Multiple Myeloma, sponsored by Stichting European Myeloma Network.

Active
Registry status
Phase 3
Development phase
759
Enrollment target
20
Study locations

NCT05257083: Active Phase 3 study of Multiple Myeloma, sponsored by Stichting European Myeloma Network.

NCT05257083 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Stichting European Myeloma Network. The registered enrollment target is 759 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT05257083, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Stichting European Myeloma Network.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
759 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Primary Outcome

Progression free survival is defined as the time from the date of randomization to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab
  • DRUG Cilta-cel
  • DRUG Bortezomib

Study Locations (20)

California

  • City of Hope - Duarte
  • UC San Diego Health Moores Cancer Center - San Diego
  • University of California San Francisco (UCSF) - San Francisco
  • Stanford University - Stanford

New York

  • Mount Sinai Medical Center - New York
  • Memorial Sloan-Kettering Cancer Center - New York
  • University of Rochester - Rochester
  • Montefiore M-E Center - The Bronx

Massachusetts

  • Massachusetts General Hospital - Boston
  • Boston Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

North Carolina

  • Levine Cancer Institute - Charlotte
  • Duke University Medical Center - Durham

Arkansas

  • University of Arkansas - Little Rock

Florida

  • Moffit Cancer Center - Tampa

Georgia

  • Emory University Hospital - Atlanta

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 759 participants
Start Date 2023-10-10
Est. Completion 2040-08
Phase Phase 3
Stichting European Myeloma Network

1 total trials

What the registry record for NCT05257083 still lists

NCT05257083 is an interventional study that assigns participants to a tested intervention. The registered 759 participants enrollment target is mid-sized for trials with a published cap, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (39% higher).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT05257083 names 20 study sites across 11 states, led by California, New York, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05257083 about?

NCT05257083 is a clinical study titled "A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed mul...

What is the current status of trial NCT05257083?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 759 participants. The study started on 2023-10-10. Estimated completion is 2040-08.

What conditions does trial NCT05257083 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05257083?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Cilta-cel (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT05257083?

This trial is sponsored by Stichting European Myeloma Network, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05257083 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05257083's enrollment target sits among peer trials

759 30th of 438 higher than 409 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02089607 · 760 participants · NA

    CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft

  • NCT04073706 · 760 participants · Phase 3

    Sentinel Node Biopsy in Endometrial Cancer

  • NCT05129228 · 760 participants · NA

    Optical Coherence Tomography of the Saphenous Vein Graft

  • NCT05787821 · 760 participants

    Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05257083, the US trial registry maintained by the National Library of Medicine. NCT05257083 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.